Article Text

Download PDFPDF

102 Cervical cancer screening using primary human papillomavirus (HPV) testing in mozambique: preliminary results of the capulana study
  1. M Pontremoli Salcedo1,
  2. C Oliveira2,
  3. V Andrade3,
  4. E Baker4,
  5. D Changule5,
  6. R Rangeiro5,
  7. ML Varon4,
  8. N Phoolcharoen6,
  9. A Mariano5,
  10. BX dos Santos5,
  11. M Chalyamba5,
  12. RF Macaringue5,
  13. SM Manhica5,
  14. JP Thomas4,
  15. M Munsell4,
  16. JHT Fregnani7,
  17. C Lorenzoni5 and
  18. KM Schmeler4
  1. 1Federal University of Health Sciences Porto Alegre/Irmandade Santa Casa de Misericordia Porto Alegre, The Obstetrics and Gynecology Department, Porto Alegre, Brazil
  2. 2Hospital de Câncer de Barretos, Molecular Oncology Research Center, Barretos, Brazil
  3. 3Hospital de Câncer de Barretos, Center for Researcher Support, Barretos, Brazil
  4. 4The University of Texas MD Anderson Cancer Center, The Department of Gynecologic Oncology and Reproductive Medicine, Houston, USA
  5. 5Hospital Geral e Centro de Saúde de Mavalane/Universidade Eduardo Mondlane, Obstetrics and Gynecology, Maputo, Mozambique
  6. 6King Chulalongkorn Memorial Hospital, Department of Obstetrics and Gynecology, Bangkok, Thailand
  7. 7AC Camargo Cancer Center, Education Department, São Paulo, Brazil


Objectives Cervical cancer is the leading cause of cancer and related deaths among women in Mozambique. There is limited access to screening and few trained personnel to manage women with abnormal results. Our objective was to implement primary HPV screening in Mozambique and navigate women with abnormal results to appropriate diagnostic and treatment services.

Methods We prospectively enrolled women aged 30 to 49 at Mavalane General Hospital in Maputo, Mozambique. All participants underwent a pelvic examination by a nurse and a cervical sample was collected and tested for HPV DNA using careHPV (Qiagen, Gaithersburg, MD, USA). Women who tested positive for HPV (HPV+) underwent visual assessment for treatment (VAT) using visual inspection with acetic acid (VIA) to assess eligibility for cryotherapy. All HPV+ women were treated with cryotherapy, loop electrosurgical excision procedure (LEEP), or referred for cancer management based on results.

Results From April 2018 to February 2019, 427 women underwent HPV testing. The median age was 39 years. 86/426 patients (20.2%) were HIV positive. 93 patients (21.8%) were HPV+ and 97.8% (91/93) returned for VAT and treatment including cryotherapy (n=68, 74.7%), LEEP (n=10, 11.0%) and referral for cancer management (n=4, 4.4%). Treatment is pending in 9 patients for cryotherapy.

Conclusions Cervical cancer screening with primary HPV DNA testing, including follow-up and treatment, was found to be feasible in Maputo, Mozambique. This study is ongoing to and includes training medical providers to diagnose and treat cervical preinvasive disease and cancer.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.